Enter to win every day in CTNOW's 21 Days of Summer Giveaways. Click here to see today's prize.


Bristol-Myers says HIV drug gets FDA incentives

Bristol-Myers said Tuesday that federal regulators will help speed up development for one of its experimental HIV drugs. The Food and Drug Administration designated the drug BMS-663068 as a breakthrough treatment, so Bristol-Myers Squibb Co. will get extra meetings with the FDA and earlier communication with scientists as it studies the drug. BMS-663068 is intended to be used with other antiretroviral drugs in adults who have already developed resistance to several other types of HIV treatments. Bristol-Myers is running late-stage clinical tests of the drug. There are six classes of HIV drugs, according to the National Institutes of Health, and patients are typically treated with drugs...